EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets

Mathijs P Scholtes, Maryam Akbarzadeh, Alexandros Galaras, J Alberto Nakauma-Gonzáles, Ameneh Bazrafshan, Vandana Solanki, Bram Torenvliet, Leila Beikmohammadi, Valeria Lozovanu, Shahla Romal, Panagiotis Moulos, Nikoleta Vavouraki und 13 weitere

Cancer Letters · 2025-04 · 614 · 217506

DOI: 10.1016/j.canlet.2025.217506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025-04. Verfasst von Mathijs P Scholtes und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Organoids, Transcription Factors, DNA-Binding Proteins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health~Holland, Erasmus University Rotterdam, Hellenic Foundation for Research and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Somatic mutations in ARID1A (AT-rich interactive domain-containing protein 1A) are present in approximately 25% of bladder cancers (BC) and are associated with poor prognosis. With a view to discover effective treatment options for ARID1A-deficient BC patients, we set out to identify targetable effectors dysregulated consequent to ARID1A deficiency. Integrative analyses of ARID1A depletion in normal organoids and data mining in publicly available datasets revealed upregulation of DNA repair and cell cycle-associated genes consequent to loss of ARID1A and identified CHEK1 (Checkpoint kinase 1) and chromosomal passenger complex member BIRC5 (Baculoviral IAP Repeat Containing 5) as therapeutically drug-able candidate molecular effectors. Ex vivo treatment of patient-derived BC tumoroids with clinically advanced small molecule inhibitors targeting CHEK1 or BIRC5 was associated with increased DNA damage signalling and apoptosis, and selectively induced cell death in tumoroids lacking ARID1A protein expression. Thus, integrating public datasets with patient-derived organoid modelling and ex-vivo drug testing can uncover key molecular effectors and mechanisms of oncogenic transformation, potentially leading to novel therapeutic strategies. Our data point to ARID1A protein expression as a suitable candidate biomarker for the selection of BC patients responsive to therapies targeting BIRC5 and CHEK1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsOrganoidsTranscription FactorsDNA-Binding ProteinsHumansSurvivinCheckpoint Kinase 1ApoptosisGene Expression Regulation, NeoplasticMolecular Targeted TherapyDNA DamageDNA Repair

Stichwörter der Autor:innen

ARID1ABC tumoroidsBladder cancerNormal bladder organoidsTargeted therapy

Substanzen

Transcription FactorsSurvivinARID1A protein, humanCheckpoint Kinase 1BIRC5 protein, humanDNA-Binding ProteinsCHEK1 protein, human

Autor:innen und Institutionen

  • Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Biochemistry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherland…
  • Institute for Fundamental Biomedical Research (IFBR), Biomedical Sciences Research Center "Alexander Fleming", the Netherlands; Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
  • Department of Biochemistry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Department of Biochemistry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; Stem Cell and Regenerative Medicine Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.
  • Institute for Fundamental Biomedical Research (IFBR), Biomedical Sciences Research Center "Alexander Fleming", the Netherlands.

Förderung

  • Health~Holland
  • Erasmus University Rotterdam
  • Hellenic Foundation for Research and Innovation

Zitieren

APA

Scholtes, M. P., Akbarzadeh, M., Galaras, A., Nakauma-Gonzáles, J. A., Bazrafshan, A., Solanki, V., Torenvliet, B., Beikmohammadi, L., Lozovanu, V., Romal, S., Moulos, P., Vavouraki, N., Kan, T. W., Algoe, M., van Royen, M. E., Sacchetti, A., van den Bosch, T. P. P., Eussen, B., de Klein, A., …, & Mahmoudi, T. (2025). Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets. Cancer Letters, 614, 217506. https://doi.org/10.1016/j.canlet.2025.217506

Vancouver

Scholtes MP, Akbarzadeh M, Galaras A, Nakauma-Gonzáles JA, Bazrafshan A, Solanki V, et al. Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets. Cancer Letters. 2025;614:217506. doi:10.1016/j.canlet.2025.217506

BibTeX
@article{Scholtes2025,
  author = {Scholtes, Mathijs P and Akbarzadeh, Maryam and Galaras, Alexandros and Nakauma-Gonzáles, J Alberto and Bazrafshan, Ameneh and Solanki, Vandana and Torenvliet, Bram and Beikmohammadi, Leila and Lozovanu, Valeria and Romal, Shahla and Moulos, Panagiotis and Vavouraki, Nikoleta and Kan, Tsung Wai and Algoe, Mahesh and van Royen, Martin E and Sacchetti, Andrea and van den Bosch, Thierry P P and Eussen, Bert and de Klein, Annelies and van Leenders, Geert J L H and Boormans, Joost L and Hatzis, Pantelis and Palstra, Robert-Jan and Zuiverloon, Tahlita C M and Mahmoudi, Tokameh},
  title = {Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets},
  journal = {Cancer Letters},
  year = {2025},
  volume = {614},
  pages = {217506},
  doi = {10.1016/j.canlet.2025.217506}
}
Kostenlos starten →